A phase II study of dibromodulcitol (DBD) in stage IV melanoma.

Abstract

Twenty-four patients were evaluated in a non-randomized study to assess the effectiveness of dibromodulcitol (DBD) in Stage IV melanoma. Patients received 100 mg/m2 of DBD orally for 35 days. The dose was escalated to 130 mg/m2 and then to 160 mg/m2 if no significant hematologic toxicity occurred. There were no objective responses, including six patients who had had no prior chemotherapy. Five patients (21%) remained stable. Median survival was 151 days. Survival favored females, nonvisceral involvement pretherapy, and patients with a disease-free interval (DFI) of greater than 1 year. None of these advantages was statistically significant. Toxicity was predominantly hematologic, but nausea, vomiting, shortness of breath, and diarrhea were also seen. Oral DBD, using this dose and schedule, does not appear efficacious in advanced disseminated melanoma.

• Authors: J Hopkins, F Richards 2nd, D Case, E Pope, D V Jackson Jr, J J Stuart, H B Muss, D R White, M R Cooper, C L Spurr
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 7 Issue 5 Pg. 555-6 (Oct 1984) ISSN: 0277-3732 [Print] United States
• PMID: 6507378 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Mitolactol

Topics

• Drug Administration Schedule
• Drug Evaluation
• Female
• Humans
• Male
• Melanoma (drug therapy)
• Mitolactol (therapeutic use)
• Skin Neoplasms (drug therapy)